Sanara MedTech, Inc. (SMTI)

Over the past six months, Sanara MedTech's stock price has declined. In March 2026, the company reported its Fourth Quarter and Full Year 2025 Financial Results, and reaffirmed its Full Year 2026 Financial Guidance. In November 2025, the company announced a strategic realignment to focus on its surgical business, discontinuing the operations of its Tissue Health Plus (THP) segment. In October 2025, Sanara MedTech was noted as a "bottom market performer" with its stock experiencing a decline. In August 2025, the company reported its second-quarter 2025 financial results, showing a 28% increase in net revenue year-over-year, but still recorded a net loss. In July 2025, insiders suffered losses following a decline in share price. Sanara MedTech Inc. is scheduled to report its First Quarter 2026 Financial Results in May 2026.

The provided search results do not contain specific information about the demand seasonality for Sanara MedTech, Inc.'s products and services. The company operates in the medical technology sector, providing surgical and wound care products, which typically have a more consistent demand driven by ongoing healthcare needs rather than strong seasonal fluctuations.

Sanara MedTech, Inc., based in Fort Worth, Texas, develops, markets, and distributes surgical solutions across the United States, focusing on improving clinical outcomes and reducing healthcare costs. The company specializes in surgical, wound care, and skin care products aimed at preventing and treating infections, including those related to biofilm in surgical environments. Its major products include CellerateRX Surgical, BIASURGE Advanced Surgical Solution, FORTIFY Tissue Repair Graft, BiFORM Bioactive Moldable Matrix, ACTIGEN Inductive Bone Matrix, ALLOCYTE Plus Advanced Viable Bone Matrix, TEXAGEN Amniotic Membrane Allograft, BIAKOS Antimicrobial Wound Gel and Cleanser, and FORTIFY FLOWABLE Extracellular Matrix. The company also has a pipeline of products under development for wound bed preparation, antimicrobials, wound re-epithelialization and closure, necrotic tissue debridement, and cell-compatible substrates.

Sanara MedTech Inc. primarily markets and distributes its products and services in the United States, with a goal to expand its geographic footprint across all 50 states. Following the acquisition of Scendia Biologics, LLC in July 2022, Sanara aimed to expand Scendia's sales beyond its primary customer base in the southeastern United States to additional states where Sanara already had a presence.

Sanara MedTech Inc. focuses on improving patient outcomes through evidence-based healing solutions and is committed to developing and commercializing innovative products. In November 2025, Sanara MedTech announced the discontinuation of its Tissue Health Plus (THP) segment to focus on its core surgical business. Despite recent stock price declines, some Wall Street analysts maintain a "Buy" or "Strong Buy" recommendation.

Sanara MedTech Inc.'s ownership structure includes institutional, insider, and retail investors. Institutional investors hold a percentage of the company's stock. Individual insiders also hold a significant proportion of Sanara MedTech Inc. The general public, mostly comprising individual investors (retail investors), holds a portion of the ownership.